Virtual Ligand Screening for Structure-based Drug Design: Approaches and Progress
Recent progress in human genomics and proteomics has significantly increased the number of macromolecular targets potentially involved in drug discovery campaigns. Today technologies like combinatorial chemistry and high-throughput screening (HTS) authorize biological assays of a large number of sma...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Academic Publishing House
2007-10-01
|
Series: | Bioautomation |
Subjects: | |
Online Access: | http://www.clbme.bas.bg/bioautomation/2007/vol_7.1/files/7_4.5.pdf |
id |
doaj-ff15b8741a9e4e538ca40e68434b1c85 |
---|---|
record_format |
Article |
spelling |
doaj-ff15b8741a9e4e538ca40e68434b1c852020-11-25T03:08:39ZengAcademic Publishing HouseBioautomation1313-261X1312-451X2007-10-0171104121Virtual Ligand Screening for Structure-based Drug Design: Approaches and ProgressOlivier SperandioMaria A. MitevaBruno O. VilloutreixRecent progress in human genomics and proteomics has significantly increased the number of macromolecular targets potentially involved in drug discovery campaigns. Today technologies like combinatorial chemistry and high-throughput screening (HTS) authorize biological assays of a large number of small molecules against the therapeutically relevant targets. However the escalating costs highlight the need of developing novel approaches while still allowing one to explore larger chemical diversity. In this respect, virtual ligand screening (VLS) is established as an attractive approach to handle large sets of compounds and to improve the "hit-rate" of drug discovery programs. Here, we review the main VLS techniques applied for structure-based drug design and we focus on key concepts in the molecular docking–scoring methodology. http://www.clbme.bas.bg/bioautomation/2007/vol_7.1/files/7_4.5.pdf Virtual screeningStructure-based drug designReview |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Olivier Sperandio Maria A. Miteva Bruno O. Villoutreix |
spellingShingle |
Olivier Sperandio Maria A. Miteva Bruno O. Villoutreix Virtual Ligand Screening for Structure-based Drug Design: Approaches and Progress Bioautomation Virtual screening Structure-based drug design Review |
author_facet |
Olivier Sperandio Maria A. Miteva Bruno O. Villoutreix |
author_sort |
Olivier Sperandio |
title |
Virtual Ligand Screening for Structure-based Drug Design: Approaches and Progress |
title_short |
Virtual Ligand Screening for Structure-based Drug Design: Approaches and Progress |
title_full |
Virtual Ligand Screening for Structure-based Drug Design: Approaches and Progress |
title_fullStr |
Virtual Ligand Screening for Structure-based Drug Design: Approaches and Progress |
title_full_unstemmed |
Virtual Ligand Screening for Structure-based Drug Design: Approaches and Progress |
title_sort |
virtual ligand screening for structure-based drug design: approaches and progress |
publisher |
Academic Publishing House |
series |
Bioautomation |
issn |
1313-261X 1312-451X |
publishDate |
2007-10-01 |
description |
Recent progress in human genomics and proteomics has significantly increased the number of macromolecular targets potentially involved in drug discovery campaigns. Today technologies like combinatorial chemistry and high-throughput screening (HTS) authorize biological assays of a large number of small molecules against the therapeutically relevant targets. However the escalating costs highlight the need of developing novel approaches while still allowing one to explore larger chemical diversity. In this respect, virtual ligand screening (VLS) is established as an attractive approach to handle large sets of compounds and to improve the "hit-rate" of drug discovery programs. Here, we review the main VLS techniques applied for structure-based drug design and we focus on key concepts in the molecular docking–scoring methodology. |
topic |
Virtual screening Structure-based drug design Review |
url |
http://www.clbme.bas.bg/bioautomation/2007/vol_7.1/files/7_4.5.pdf |
work_keys_str_mv |
AT oliviersperandio virtualligandscreeningforstructurebaseddrugdesignapproachesandprogress AT mariaamiteva virtualligandscreeningforstructurebaseddrugdesignapproachesandprogress AT brunoovilloutreix virtualligandscreeningforstructurebaseddrugdesignapproachesandprogress |
_version_ |
1724664977733713920 |